Pharvaris is hiring a #Global Head of #Quality. To support our primary programs aimed at bringing new, oral options to people living with hereditary angioedema (HAE), we have an opportunity for a highly driven Global Head of Quality to join and take #strategicdirection of our Quality department as the organization evolves. This newly created position will ensure that we continue to follow #FDA and international regulatory requirements for our Small Molecule Drug Substance (DS) and Drug Product (DP) as we continue down clinical pathways towards a potential commercial future. The Global Head of Quality will be based on the East Coast of the United States (Hybrid/Remote) and will be attached to our operations in the Boston, MA area. They will report to the VP, Regulatory Affairs & Quality. They will work closely with our existing Quality and Technical Operations teams to ensure that Quality is at the heart of everything we do. SaraBeth Hahn, PharmD, RPh For more information, please explore our careers website: https://lnkd.in/d3zgSkK
Pharvaris’ Post
More Relevant Posts
-
Do you want to help us pioneer science for patient choice? Join our growing team. We’re #hiring now for the following positions: #Global Head of #Quality Reporting to SaraBeth Hahn, PharmD, RPh #GCPoversight and #Compliance Lead Reporting to Vinay Edwin, MPH Senior #MedicalScience #Liaison, West Coast Reporting to Kenneth Robinson Visit https://lnkd.in/d3zgSkK to review our open positions and apply now. #drugdevelopment #HAEawareness #NowHiring
To view or add a comment, sign in
-
-
People with #HereditaryAgioedema (#HAE) have a personal choice of two distinct therapeutic strategies based on clinical assessment: treatment of attacks (on-demand) or prevention of attacks (prophylactic). Our goal is to develop novel, oral on-demand and prophylactic alternatives with #deucrictibant — the only oral B2 receptor antagonist currently in clinical development for the treatment of HAE to our knowledge. Visit our website to learn more about how our treatment strategy aims to improve the quality of life for people with HAE: https://lnkd.in/gzNk4GdP #ClinicalTrials #HAEtreatment
To view or add a comment, sign in
-
-
On May 16, we joined together with HAE International (HAEi) and Hereditary Angioedema Association - HAEA to celebrate #HAEday. An important part of the celebration is #active4HAE, a global challenge to raise awareness about #HereditaryAngioedema (#HAE) through physical activity. At Team Pharvaris, we did our part by participating in a 27-minute walk to represent the fact that people with HAE suffer 27 swelling attacks on average per year. How did you celebrate HAE day? Let us know with a comment below. #HAEawareness
To view or add a comment, sign in
-
-
Pharvarians presented #deucrictibant data at the European Academy of Allergy and Clinical Immunology - EAACI Congress and the Eastern Allergy Conference this past weekend. We are grateful to the #HAE community for the continued #collaboration and support of #drugdevelopment. #TBT
To view or add a comment, sign in
-
-
Pharvaris recently presented data highlighting the unique #pharmacological and #clinical properties of #deucrictibant for the treatment and prevention of #HAE attacks at the European Academy of Allergy and Clinical Immunology - EAACI Congress, the Eastern Allergy Conference, and the International Drug Discovery Sciences & Technology (IDDST) Congress. Read more about the data presented here: https://lnkd.in/eNePsr_R
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses - Pharvaris N.V.
ir.pharvaris.com
To view or add a comment, sign in
-
Many faces, one family. Pharvaris is a proud supporter of hae day :-) to raise #awareness of #hae #hereditaryangioedema. Today, we celebrate #HAEday along with organizations like HAE International (HAEi) and Hereditary Angioedema Association - HAEA.
To view or add a comment, sign in
-
The Pharvaris team is presenting at the 20th Annual Congress of International Drug Discovery Science and Technology (#IDDST); the 2024 Eastern Allergy Conference (#EAC); and the European Academy of Allergy and Clinical Immunology - EAACI (#EAACI) Congress 2024. Click here to find out more about our #clinical and #nonclinical presentations: https://lnkd.in/g6H2DEsf
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses - Pharvaris N.V.
ir.pharvaris.com
To view or add a comment, sign in
-
This afternoon, Pharvaris reported our first quarter 2024 financial results and provided a business update. Read the full PR here: https://lnkd.in/giW4R_Hx Berndt Modig, Pharvaris' CEO, stated, "Pharvaris is executing from a position of financial and operational strength as we enroll in RAPIDe-3, our Phase 3 on-demand study of deucrictibant, and prepare for initiation of CHAPTER-3, our Phase 3 prophylactic study of deucrictibant. We believe deucrictibant has the potential to be the preferred therapeutic option for both the treatment and prevention of HAE attacks. Pharvaris continues to further build its team and infrastructure to support two late-stage clinical trials and prepare for the commercial launch of deucrictibant for people living with HAE.”
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update - Pharvaris N.V.
ir.pharvaris.com
To view or add a comment, sign in